Enliven Therapeutics reported a net loss of $25.335 million for the second quarter ended June 30, 2025, compared to a net loss of $19.950 million for the same period in 2024. Research and development expenses for Q2 2025 were $21.491 million, an increase from $18.826 million in Q2 2024. General and administrative expenses also rose to $7.093 million from $5.777 million year-over-year.
The company's cash, cash equivalents, and marketable securities significantly increased to $490.503 million as of June 30, 2025, up from $313.440 million at December 31, 2024. This strong cash position is expected to fund operations into the first half of 2029, extending the company's financial runway. The increase in cash was primarily due to the approximately $230 million gross proceeds from a recent public offering.
Enliven reiterated positive clinical data for ELVN-001 from its Phase 1 trial, reporting a cumulative Major Molecular Response rate of 47% with 32% of patients achieving MMR by 24 weeks. ELVN-001 demonstrated a favorable safety and tolerability profile across all dose levels. The company expects to initiate its first Phase 3 pivotal trial for ELVN-001 in 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.